Efficacy and Safety of Reslizumab in Pediatric Patients With Eosinophilic Asthma

Study Title
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Teva Identifier
C38072/3082
ClinicalTrials.gov Identifier
NCT01287039
Study Status
Completed
Trial Condition(s)
Eosinophilic Asthma
Interventions
Drug: Reslizumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
12 Years to 75 Years
Trial Duration
04/01/2011 - 03/01/2014
Phase
Phase 3

Study Type

Interventional